See the DrugPatentWatch profile for Mirabegron
Mirabegron is a medication used to treat overactive bladder (OAB) [1]. It is a beta-3 adrenergic agonist that relaxes the detrusor muscle in the bladder, increasing its storage capacity [1][2]. This can help reduce symptoms such as urinary urgency, frequency, and incontinence [1].
How does Mirabegron work to treat overactive bladder?
Mirabegron targets beta-3 adrenergic receptors located in the detrusor muscle of the bladder wall [1][2]. By stimulating these receptors, it causes the muscle to relax. This relaxation increases the volume of the bladder the patient can hold before feeling the urge to urinate and reduces involuntary bladder contractions that lead to urgency and leakage [1][2]. Unlike anticholinergic OAB medications, mirabegron does not typically cause dry mouth [3].
What is the difference between Mirabegron and other OAB treatments?
Mirabegron offers an alternative mechanism of action compared to traditional anticholinergic drugs for OAB [3]. Anticholinergics work by blocking acetylcholine, a neurotransmitter that causes bladder muscle contractions. Mirabegron's action on beta-3 receptors provides a different pathway to relax the bladder muscle, potentially offering a favorable side effect profile for some patients, particularly regarding dry mouth [3].
When does the patent for Mirabegron expire?
The primary patent for mirabegron, US Patent No. 8,822,455, is scheduled to expire in September 2027 [4]. However, other related patents and potential legal challenges could affect the exact timeline of generic availability [4]. Information on patent expirations and challenges for Mirabegron can be found on DrugPatentWatch.com [4].
Can generic versions of Mirabegron be available before patent expiry?
Generic drug manufacturers often file Abbreviated New Drug Applications (ANDAs) to challenge existing patents and seek early market entry [4]. The actual availability of generic mirabegron will depend on the outcomes of any patent litigation and the U.S. Food and Drug Administration's (FDA) approval process for ANDAs [4].
Who makes Mirabegron and its generic versions?
Mirabegron is currently marketed by Astellas Pharma under the brand name Myrbetriq [1]. Once patents expire and generic versions are approved, other pharmaceutical companies will likely manufacture and market generic mirabegron [4].
What are the side effects of Mirabegron?
Common side effects reported with mirabegron include high blood pressure, nasopharyngitis (common cold symptoms), urinary tract infections, and constipation [1]. Less common but serious side effects can include severe allergic reactions and worsening of existing glaucoma [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
What is the typical cost of Mirabegron?
The cost of mirabegron can vary significantly based on insurance coverage, pharmacy, and whether a generic version becomes available [5]. Brand-name mirabegron can be expensive, and the introduction of generic alternatives typically leads to lower prices [5]. Information on pricing and potential savings can be obtained through prescription savings programs and by comparing prices at different pharmacies [5].
What are the clinical trial results for Mirabegron?
Clinical trials have demonstrated that mirabegron is effective in reducing the number of incontinence episodes and urinary urgency in patients with overactive bladder [1][2]. Studies have shown statistically significant improvements in patient-reported outcomes compared to placebo [2]. For example, a Phase III trial showed a significant reduction in micturition frequency and incontinence episodes [2].
What regulatory approvals does Mirabegron have?
Mirabegron has received regulatory approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of overactive bladder [1][6]. In the U.S., it is available as Myrbetriq, and in Europe, it is marketed under various brand names, including Betmiga [6].
What are the risks associated with Mirabegron use?
The primary risk associated with mirabegron is an increase in blood pressure, which requires regular monitoring by a healthcare professional [1]. Patients with uncontrolled high blood pressure should not take mirabegron [1]. Other risks include urinary retention in patients with bladder outlet obstruction or those taking muscarinic anticholinergic drugs for OAB [1].
What are patient concerns about Mirabegron?
Patient concerns often revolve around the effectiveness of the medication in managing OAB symptoms, potential side effects like increased blood pressure, and the cost of treatment, especially for long-term use [5]. Some patients may also inquire about the duration of treatment and when they can expect to see improvements [1].
---
Sources:
[1] https://www.rxlist.com/script/consumer/23/index.jsp?drugid=24770&monographid=24770&name=MIRABEGron&method=display
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710234/
[3] https://www.health.harvard.edu/womens-health/whats-new-in-overactive-bladder-treatment
[4] https://www.drugpatentwatch.com/search/mirabegron
[5] https://www.goodrx.com/mirabegron
[6] https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga